Depletion of tumor-associated macrophages enhances the anti-tumor immunity induced by a toll-like receptor agonist-conjugated peptide

Human Vaccines and Immunotherapeutics

Volumn 10, Issue 11, 2014, Pages 3241-3250

  Shen, Kuan Yin ^a,b   Song, Ying Chyi ^b   Chen, I Hua ^b   Chong, Pele ^b,c   Liu, Shih Jen ^a,b,c  

^a NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Cyclooxygenase; IL10; Immunotherapy; Macrophage; Peptide; Toll like receptor

Indexed keywords

ANTINEOPLASTIC AGENT; GAMMA INTERFERON; PAM2IDG PEPTIDE; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 6; UNCLASSIFIED DRUG; BLOCKING ANTIBODY; CLODRONIC ACID; CYCLOOXYGENASE 2 INHIBITOR; INTERLEUKIN 10 RECEPTOR; LIPOPEPTIDE; PALMITIC ACID; PROTEIN E7; TLR2 PROTEIN, MOUSE; TLR6 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW DERIVED DENDRITIC CELL; CANCER INHIBITION; CELL MATURATION; CELL POPULATION; CONCENTRATION RESPONSE; CYTOKINE PRODUCTION; DRUG EFFECT; IMMUNIZATION; MALIGNANT NEOPLASTIC DISEASE; MOUSE; NONHUMAN; SIGNAL TRANSDUCTION; SURVIVAL RATE; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; TUMOR VOLUME; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CHEMISTRY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; IMMUNOLOGY; IMMUNOTHERAPY; LIPOYLATION; LYMPHOCYTE ACTIVATION; MACROPHAGE; NEOPLASMS;

ANIMALS; ANTIBODIES, BLOCKING; CLODRONIC ACID; CYCLOOXYGENASE 2 INHIBITORS; DENDRITIC CELLS; IMMUNIZATION; IMMUNOTHERAPY; LIPOPEPTIDES; LIPOYLATION; LYMPHOCYTE ACTIVATION; MACROPHAGES; MICE; MICE, INBRED C57BL; NEOPLASMS; PALMITIC ACID; PAPILLOMAVIRUS E7 PROTEINS; RECEPTORS, INTERLEUKIN-10; SURVIVAL RATE; T-LYMPHOCYTES, CYTOTOXIC; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 6;

EID: 84921753458     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.29275     Document Type: Article

References (48)

1. Cho HJ, Oh YK, Kim YB. Advances in human papilloma virus vaccines: a patent review. Expert opinion on therapeutic patents 2011; 21:295-309.
2. Woodman CB, Collins SI, Young LS. The natural history of cervical HPV infection: unresolved issues. Nat Rev Cancer 2007; 7:11-22; PMID:17186016; http://dx.doi.org/10.1038/nrc2050
3. Hebner CM, Laimins LA. Human papillomaviruses: basic mechanisms of pathogenesis and oncogenicity. Rev Med Virol 2006; 16:83-97; PMID:16287204; http://dx.doi.org/10.1002/rmv.488
4. Hung CF, Ma B, Monie A, Tsen SW, Wu TC. Therapeutic human papillomavirus vaccines: current clinical trials and future directions. Expert Opin Biol Ther 2008; 8:421-39; PMID:18352847; http://dx.doi.org/10.1517/14712598.8.4.421
5. Wieking BG, Vermeer DW, Spanos WC, Lee KM, Vermeer P, Lee WT, Xu Y, Gabitzsch ES, Balcaitis S, Balint JP Jr., et al. A non-oncogenic HPV 16 E6/E7 vaccine enhances treatment of HPV expressing tumors. Cancer Gene Ther 2012; 19:667-74; PMID:22918471; http://dx.doi.org/10.1038/cgt.2012.55
6. Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, Berends-van derMeer DM, Vloon AP, Essahsah F, Fathers LM, Offringa R, Drijfhout JW, et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 2009; 361:1838-47; PMID:19890126; http://dx.doi.org/10.1056/NEJMoa0810097
7. Zwaveling S, Ferreira Mota SC, Nouta J, Johnson M, Lipford GB, Offringa R, van der Burg SH, Melief CJ. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J Immunol 2002; 169:350-8; PMID:12077264; http://dx.doi.org/10.4049/jimmunol.169.1.350
8. Prajeeth CK, Jirmo AC, Krishnaswamy JK, Ebensen T, Guzman CA, Weiss S, Constabel H, Schmidt RE, Behrens GM. The synthetic TLR2 agonist BPPcysMPEG leads to efficient cross-priming against co-administered and linked antigens. Eur J Immunol 2010; 40:1272-83; PMID:20213735; http://dx.doi.org/10.1002/eji.200939790
9. Andrieu M, Loing E, Desoutter JF, Connan F, Choppin J, Gras-Masse H, Hanau D, Dautry-Varsat A, Guillet JG, Hosmalin A. Endocytosis of an HIV-derived lipopeptide into human dendritic cells followed by class I-restricted CD8(+) T lymphocyte activation. Eur J Immunol 2000; 30:3256-65; PMID:11093141; http://dx.doi.org/10.1002/1521-4141(200011)30:11≤3256::AID-IMMU3256≤3.0.CO;2-H
10. Gahéry-Ségard H, Pialoux G, Charmeteau B, Sermet S, Poncelet H, Raux M, Tartar A, Lévy JP, Gras-Masse H, Guillet JG. Multiepitopic B- and T-cell responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine. J Virol 2000; 74:1694-703; PMID:10644339; http://dx.doi.org/10.1128/JVI.74.4.1694-1703.2000
11. Xu DH, Zhou CH, Xia YP, Qiu ZY, Wu YZ, Jia ZC, Zhou W. Cytotoxic T lymphocyte response induced by an improved synthetic lipopeptide vaccine against cervical cancer. Acta Pharmacol Sin 2007; 28:695-702; PMID:17439726; http://dx.doi.org/10.1111/j.1745-7254.2007.00538.x
12. Baz A, Buttigieg K, Zeng W, Rizkalla M, Jackson DC, Groves P, Kelso A. Branched and linear lipopeptide vaccines have different effects on primary CD4+ and CD8+ T-cell activation but induce similar tumor-protective memory CD8+ T-cell responses. Vaccine 2008; 26:2570-9; PMID:18420312; http://dx.doi.org/10.1016/j.vaccine.2008.03.022
13. Andrieu M, Desoutter JF, Loing E, Gaston J, Hanau D, Guillet JG, Hosmalin A. Two human immunodeficiency virus vaccinal lipopeptides follow different crosspresentation pathways in human dendritic cells. J Virol 2003; 77:1564-70; PMID:12502869; http://dx.doi.org/10.1128/JVI.77.2.1564-1570.2003
14. Song YC, Chou AH, Homhuan A, Huang MH, Chiang SK, Shen KY, Chuang PW, Leng CH, Tao MH, Chong P, et al. Presentation of lipopeptide by dendritic cells induces anti-tumor responses via an endocytosis-independent pathway in vivo. J Leukoc Biol 2011; 90:323-32; PMID:21521754; http://dx.doi.org/10.1189/jlb.0111046
15. Chua BY, Zeng W, Lau YF, Jackson DC. Comparison of lipopeptide-based immunocontraceptive vaccines containing different lipid groups. Vaccine 2007; 25:92-101; PMID:17055123; http://dx.doi.org/10.1016/j. vaccine.2006.07.012
16. Azuma M, Sawahata R, Akao Y, Ebihara T, Yamazaki S, Matsumoto M, Hashimoto M, Fukase K, Fujimoto Y, Seya T. The peptide sequence of diacyl lipopeptides determines dendritic cell TLR2-mediated NK activation. PLoS One 2010; 5:5; PMID:20824059; http://dx.doi.org/10.1371/journal.pone.0012550
17. Zeng W, Horrocks KJ, Robevska G, Wong CY, Azzopardi K, Tauschek M, Robins-Browne RM, Jackson DC. A modular approach to assembly of totally synthetic self-adjuvanting lipopeptide-based vaccines allows conformational epitope building. J Biol Chem 2011; 286:12944-51; PMID:21321114; http://dx.doi.org/10.1074/jbc.M111.227744
18. Prajeeth CK, Jirmo AC, Krishnaswamy JK, Ebensen T, Guzman CA, Weiss S, Constabel H, Schmidt RE, Behrens GM. The synthetic TLR2 agonist BPPcysMPEG leads to efficient cross-priming against co-administered and linked antigens. Eur J Immunol 2010; 40: 1272-83; PMID:20213735; http://dx.doi.org/10.1002/eji.200939790
19. BenMohamed L, Wechsler SL, Nesburn AB. Lipopeptide vaccines-yesterday, today, and tomorrow. Lancet Infect Dis 2002; 2:425-31; PMID:12127354; http://dx.doi.org/10.1016/S1473-3099(02)00318-3
20. Sica A, Bronte V. Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest 2007; 117:1155-66; PMID:17476345; http://dx.doi.org/10.1172/JCI31422
21. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002; 23:549-55; PMID:12401408; http://dx.doi.org/10.1016/S1471-4906(02)02302-5
22. Hao NB, Lü MH, Fan YH, Cao YL, Zhang ZR, Yang SM. Macrophages in tumor microenvironments and the progression of tumors. Clin Dev Immunol 2012; 2012:948098; PMID:22778768; http://dx.doi.org/10.1155/2012/948098
23. Bergot AS, Kassianos A, Frazer IH, Mittal D. New Approaches to Immunotherapy for HPV Associated Cancers. Cancers (Basel) 2011; 3:3461-95; PMID:24212964; http://dx.doi.org/10.3390/cancers3033461
24. Guzmán-Olea E, Bermúdez-Morales VH, Peralta-Zaragoza O, Torres-Poveda K, Madrid-Marina V. Molecular Mechanism and Potential Targets for Blocking HPV-Induced Lesion Development. J Oncol 2012; 2012:278312; PMID:22220169; http://dx.doi.org/10.1155/2012/278312
25. Lepique AP, Daghastanli KR, Cuccovia IM, Villa LL. HPV16 tumor associated macrophages suppress antitumor T cell responses. Clin Cancer Res 2009; 15:4391-400; PMID:19549768; http://dx.doi.org/10.1158/1078-0432.CCR-09-0489
26. Allavena P, Mantovani A. Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment. Clin Exp Immunol 2012; 167:195-205; PMID:22235995; http://dx.doi.org/10.1111/j.1365-2249.2011.04515.x
27. Predina J, Eruslanov E, Judy B, Kapoor V, Cheng G, Wang LC, Sun J, Moon EK, Fridlender ZG, Albelda S, et al. Changes in the local tumor microenvironment in recurrent cancers may explain the failure of vaccines after surgery. Proc Natl Acad Sci U S A 2013; 110: E415-24; PMID:23271806; http://dx.doi.org/10.1073/pnas.1211850110
28. Sha W, Brüne B, Weigert A. The multi-faceted roles of prostaglandin E2 in cancer-infiltrating mononuclear phagocyte biology. Immunobiology 2012; 217:1225-32; PMID:22727331; http://dx.doi.org/10.1016/j.imbio.2012.05.001
29. Buwitt-Beckmann U, Heine H, Wiesmüller KH, Jung G, Brock R, Akira S, Ulmer AJ. Toll-like receptor 6-independent signaling by diacylated lipopeptides. Eur J Immunol 2005; 35:282-9; PMID:15580661; http://dx.doi.org/10.1002/eji.200424955
30. Wu W, Li R, Malladi SS, Warshakoon HJ, Kimbrell MR, Amolins MW, Ukani R, Datta A, David SA. Structure-activity relationships in toll-like receptor-2 agonistic diacylthioglycerol lipopeptides. J Med Chem 2010; 53:3198-213; PMID:20302301; http://dx.doi.org/10.1021/jm901839g
31. Heusinkveld M, van der Burg SH. Identification and manipulation of tumor associated macrophages in human cancers. J Transl Med 2011; 9:216; PMID:22176642; http://dx.doi.org/10.1186/1479-5876-9-216
32. Chang LS, Leng CH, Yeh YC, Wu CC, Chen HW, Huang HM, Liu SJ. Toll-like receptor 9 agonist enhances anti-tumor immunity and inhibits tumor-associated immunosuppressive cells numbers in a mouse cervical cancer model following recombinant lipoprotein therapy. Mol Cancer 2014; 13:60; PMID:24642245; http://dx.doi.org/10.1186/1476-4598-13-60
33. Huang CY, Chen JJ, Shen KY, Chang LS, Yeh YC, Chen IH, Chong P, Liu SJ, Leng CH. Recombinant lipidated HPV E7 induces a Th-1-biased immune response and protective immunity against cervical cancer in a mouse model. PLoS One 2012; 7:e40970; PMID:22815882; http://dx.doi.org/10.1371/journal.pone.0040970
34. Chua BY, Eriksson EM, Brown LE, Zeng W, Gowans EJ, Torresi J, Jackson DC. A self-adjuvanting lipopep-tide-based vaccine candidate for the treatment of hepatitis C virus infection. Vaccine 2008; 26:4866-75; PMID:18455278; http://dx.doi.org/10.1016/j.vaccine.2008.03.032
35. Zanin-Zhorov A, Cahalon L, Tal G, Margalit R, Lider O, Cohen IR. Heat shock protein 60 enhances CD4+ CD25+ regulatory T cell function via innate TLR2 signaling. J Clin Invest 2006; 116:2022-32; PMID:16767222; http://dx.doi.org/10.1172/JCI28423
36. Dang Y, Wagner WM, Gad E, Rastetter L, Berger CM, Holt GE, Disis ML. Dendritic cell-activating vaccine adjuvants differ in the ability to elicit antitumor immunity due to an adjuvant-specific induction of immunosuppressive cells. Clin Cancer Res 2012; 18:3122-31; PMID:22510348; http://dx.doi.org/10.1158/1078-0432.CCR-12-0113
37. Sato T, Terai M, Tamura Y, Alexeev V, Mastrangelo MJ, Selvan SR. Interleukin 10 in the tumor microenvironment: a target for anticancer immunotherapy. Immunol Res 2011; 51:170-82; PMID:22139852; http://dx.doi.org/10.1007/s12026-011-8262-6
38. Bolpetti A, Silva JS, Villa LL, Lepique AP. Interleukin-10 production by tumor infiltrating macrophages plays a role in Human Papillomavirus 16 tumor growth. BMC Immunol 2010; 11:27; PMID:20525400; http://dx.doi.org/10.1186/1471-2172-11-27
39. Mahic M, Yaqub S, Johansson CC, Taskén K, Aandahl EM. FOXP3+CD4+CD25+ adaptive regulatory T cells express cyclooxygenase-2 and suppress effector T cells by a prostaglandin E2-dependent mechanism. J Immunol 2006; 177:246-54; PMID:16785520; http://dx.doi.org/10.4049/jimmunol.177.1.246
40. Eberstal S, Sandén E, Fritzell S, Darabi A, Visse E, Siesjö P. Intratumoral COX-2 inhibition enhances GM-CSF immunotherapy against established mouse GL261 brain tumors. Int J Cancer 2014; 134:2748-53; PMID:24243648; http://dx.doi.org/10.1002/ijc.28607
41. Demasi M, Cleland LG, Cook-Johnson RJ, Caughey GE, James MJ. Effects of hypoxia on monocyte inflammatory mediator production: Dissociation between changes in cyclooxygenase-2 expression and eicosanoid synthesis. J Biol Chem 2003; 278:38607-16; PMID:12874281; http://dx.doi.org/10.1074/jbc.M305944200
42. Aichele P, Zinke J, Grode L, Schwendener RA, Kaufmann SH, Seiler P. Macrophages of the splenic marginal zone are essential for trapping of blood-borne particulate antigen but dispensable for induction of specific T cell responses. J Immunol 2003; 171:1148-55; PMID:12874200; http://dx.doi.org/10.4049/jimmunol.171.3.1148
43. Le Borgne M, Etchart N, Goubier A, Lira SA, Sirard JC, van Rooijen N, Caux C, Äit-Yahia S, Vicari A, Kaiserlian D, et al. Dendritic cells rapidly recruited into epithelial tissues via CCR6/CCL20 are responsible for CD8+ T cell crosspriming in vivo. Immunity 2006; 24:191-201; PMID:16473831; http://dx.doi.org/10.1016/j.immuni.2006.01.005
44. Guth AM, Hafeman SD, Dow SW. Depletion of phagocytic myeloid cells triggers spontaneous T cell-and NK cell-dependent antitumor activity. Oncoimmunology 2012; 1:1248-57; PMID:23243588; http://dx.doi.org/10.4161/onci.21317
45. Chen HW, Leng CH, Liu HY, Cheng WF, Chang YW, Wu PY, Lien SP, Huang TY, Chiang SK, Lin MH, et al. Identification of HLA-A11-restricted CTL epitopes derived from HPV type 18 using DNA immunization. Cancer Biol Ther 2009; 8:2025-32; PMID:19738415; http://dx.doi.org/10.4161/cbt.8.21.9732
46. Chan PK, Liu SJ, Cheung TH, Yeo W, Ngai SM, Cheung JL, Chong P, Man S. T-cell response to human papillomavirus type 58 L1, E6, And E7 peptides in women with cleared infection, cervical intraepithelial neoplasia, or invasive cancer. Clin Vaccine Immunol 2010; 17:1315-21; PMID:20668141; http://dx.doi.org/10.1128/CVI.00105-10
47. Chan PK, Liu SJ, Cheung JL, Cheung TH, Yeo W, Chong P, Man S. T-cell response to human papillomavirus type 52 L1, E6, and E7 peptides in women with transient infection, cervical intraepithelial neoplasia, and invasive cancer. J Med Virol 2011; 83:1023-30; PMID:21503915; http://dx.doi.org/10.1002/jmv.21889
48. Chen HW, Liu SJ, Liu HH, Kwok Y, Lin CL, Lin LH, Chen MY, Tsai JP, Chang LS, Chiu FF, et al. A novel technology for the production of a heterologous lipoprotein immunogen in high yield has implications for the field of vaccine design. Vaccine 2009; 27:1400-9; PMID:19150476; http://dx.doi.org/10.1016/j.vaccine.2008.12.043